We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
Read MoreHide Full Article
Allscripts Healthcare Solutions Inc. (MDRX - Free Report) is scheduled to release fourth-quarter 2016 results on Feb 16.
Allscripts Healthcare has an impressive track of beating estimates in all the four trailing quarters. In the last reported quarter, it recorded a positive earnings surprise of 10.00%, bringing the four-quarter average to 5.00%. Over the past three months, Allscripts Healthcare returned almost 16.68%, which is higher than the Zacks categorized Medical Information Systems sub-industry’s gain of roughly 6.55%. Also, Allscripts Healthcare has a decent earnings surprise history, as evident from the chart below.
Allscripts Healthcare Solutions, Inc. Price and EPS Surprise
Our quantitative model shows that Allscripts Healthcare is likely to beat earnings because it has the perfect combination of two key ingredients. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is the case here as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +8.33%. This is because the Most Accurate estimate of 13 cents is pegged higher than the Zacks Consensus Estimate of 12 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Allscripts Healthcare carries a Zacks Rank #3. The combination of Allscripts Healthcare’s favorable Zacks Rank and positive ESP makes us reasonably confident of an earnings beat.
Factors at Play
In the fourth quarter, we believe that regular contract wins and strategic collaborations will consistently drive Allscripts’ top line. The company expects bookings to exceed $400 million. This represents a company record and annual growth of over 17%. Also, the company expects non-GAAP revenues between $420 million and $435 million, adjusted net EBITDA between $70 million and $80 million, and non-GAAP earnings per share between 14 cents and 16 cents.
Further, the growing adoption of Allscripts’ products and services like the Sunrise platform, FollowMyHealth, Touchworks EHR, EPSi and dbMotion will drive market traction. Moreover, the new share repurchase program will also boost earnings.
Overall, the activities of Allscripts Healthcare during the fourth quarter were adequate to win analysts’ confidence. As a result, the Zacks Consensus Estimate for the quarter rose 2 cents to 12 cents per share in the last 30 days.
Other Stocks that Warrant a Look
Here are some other companies you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter:
DaVita HealthCare Partners Inc. (DVA - Free Report) has an Earnings ESP of +4.40% and a Zacks Rank #3. Additionally, on average, the stock recorded a positive surprise of almost 3.77% in the trailing four quarters.
Exilixis, Inc. (EXEL - Free Report) has an Earnings ESP of +200% and a Zacks Rank #2. The stock registered a positive earnings surprise of 107.69% in the last reported quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
Allscripts Healthcare Solutions Inc. (MDRX - Free Report) is scheduled to release fourth-quarter 2016 results on Feb 16.
Allscripts Healthcare has an impressive track of beating estimates in all the four trailing quarters. In the last reported quarter, it recorded a positive earnings surprise of 10.00%, bringing the four-quarter average to 5.00%. Over the past three months, Allscripts Healthcare returned almost 16.68%, which is higher than the Zacks categorized Medical Information Systems sub-industry’s gain of roughly 6.55%. Also, Allscripts Healthcare has a decent earnings surprise history, as evident from the chart below.
Allscripts Healthcare Solutions, Inc. Price and EPS Surprise
Allscripts Healthcare Solutions, Inc. Price and EPS Surprise | Allscripts Healthcare Solutions, Inc. Quote
Earnings Whispers
Our quantitative model shows that Allscripts Healthcare is likely to beat earnings because it has the perfect combination of two key ingredients. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is the case here as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +8.33%. This is because the Most Accurate estimate of 13 cents is pegged higher than the Zacks Consensus Estimate of 12 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Allscripts Healthcare carries a Zacks Rank #3. The combination of Allscripts Healthcare’s favorable Zacks Rank and positive ESP makes us reasonably confident of an earnings beat.
Factors at Play
In the fourth quarter, we believe that regular contract wins and strategic collaborations will consistently drive Allscripts’ top line. The company expects bookings to exceed $400 million. This represents a company record and annual growth of over 17%. Also, the company expects non-GAAP revenues between $420 million and $435 million, adjusted net EBITDA between $70 million and $80 million, and non-GAAP earnings per share between 14 cents and 16 cents.
Further, the growing adoption of Allscripts’ products and services like the Sunrise platform, FollowMyHealth, Touchworks EHR, EPSi and dbMotion will drive market traction. Moreover, the new share repurchase program will also boost earnings.
Overall, the activities of Allscripts Healthcare during the fourth quarter were adequate to win analysts’ confidence. As a result, the Zacks Consensus Estimate for the quarter rose 2 cents to 12 cents per share in the last 30 days.
Other Stocks that Warrant a Look
Here are some other companies you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter:
DaVita HealthCare Partners Inc. (DVA - Free Report) has an Earnings ESP of +4.40% and a Zacks Rank #3. Additionally, on average, the stock recorded a positive surprise of almost 3.77% in the trailing four quarters.
The Cooper Companies (COO - Free Report) has an Earnings ESP of +2.69% and a Zacks Rank #2. The stock posted a positive surprise of almost 6.32% in the last four quarters. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exilixis, Inc. (EXEL - Free Report) has an Earnings ESP of +200% and a Zacks Rank #2. The stock registered a positive earnings surprise of 107.69% in the last reported quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>